undamentalytics Newsletter

Davis George Eric: insider trades

Officer at Biomarin Pharmaceutical Inc. No open-market purchases and 27 sales not made under a pre-set plan, reported from August 24, 2010 to September 3, 2026.

What happened after Davis George Eric’s sales?

After their sales, the shares moved −4.6% against the index over 12 months on average (a negative figure means selling was the right call); 56% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Davis George Eric: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 26 −1.5% −2.4% 62% 12 −0.49 0.63 No reliable evidence
Sales, 12 months after the report 25 −4.6% −9.7% 56% 11 −0.30 0.77 No reliable evidence
Sales, 12 months after the trade 25 −4.1% −12.9% 60% 11 −0.21 0.84 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Biomarin Pharmaceutical Inc BMRN EVP, Chief Legal Officer027August 24, 2010September 3, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 3, 2026September 2, 2026 BMRN Sale $1,163,678 not yetnot yetnot yet
February 26, 2026February 26, 2026 BMRN Sale $1,599,103 −17.8%not yetnot yet
August 9, 2023August 8, 2023 BMRN Sale $983,620 −4.3%−23.3%−22.9%
August 11, 2022August 9, 2022 BMRN Sale $4,914,664 −5.2%−10.0%−15.2%
September 18, 2018September 14, 2018 BMRN Sale $220,389 −0.6%−29.8%−30.1%
September 17, 2018September 13, 2018 BMRN Sale $1,194,840 +1.9%−29.2%−30.7%
December 4, 2017November 30, 2017 BMRN Sale $102,768 −3.3%+13.9%+6.0%
June 7, 2017June 5, 2017 BMRN Sale $862,240 −1.3%−15.6%−13.6%
May 9, 2017May 5, 2017 BMRN Sale $250,850 −9.0%−16.3%−21.2%
May 10, 2016May 9, 2016 BMRN Sale $1,247,579 +5.3%−9.7%−10.2%
March 16, 2016March 14, 2016 BMRN Sale $172,075 +2.1%−1.3%−12.9%
May 19, 2015May 18, 2015 BMRN Sale $320,415 +7.7%−31.7%−31.5%
March 17, 2015March 13, 2015 BMRN Sale $1,813,050 −2.5%−37.9%−30.8%
March 4, 2015March 2, 2015 BMRN Sale $2,491,130 +5.8%−20.8%−14.6%
November 3, 2014October 30, 2014 BMRN Sale $1,248,000 +11.5%+28.3%+35.7%
May 15, 2013May 14, 2013 BMRN Sale $1,406,800 −2.2%−26.7%−33.6%
May 14, 2013May 13, 2013 BMRN Sale $179,461 −4.9%−30.4%−35.1%
May 7, 2013May 3, 2013 BMRN Sale $393,330 −7.2%−30.3%−29.0%
March 6, 2013March 4, 2013 BMRN Sale $240,720 −10.1%+0.9%+8.7%
February 28, 2013February 27, 2013 BMRN Sale $455,200 −2.7%+9.7%+22.8%
November 19, 2012November 19, 2012 BMRN Sale $357,106 +4.0%+9.3%+7.1%
November 14, 2012November 9, 2012 BMRN Sale $4,800,118 +5.0%+10.0%−2.2%
May 15, 2012May 11, 2012 BMRN Sale $1,603,895 −6.1%+33.9%+53.2%
March 11, 2011March 9, 2011 BMRN Sale $146,940 +8.1%+30.5%+35.3%
November 24, 2010November 24, 2010 BMRN Sale $137,500 −23.8%+17.3%+18.9%
November 5, 2010November 4, 2010 BMRN Sale $267,909 −8.0%+21.3%+20.9%
August 24, 2010August 20, 2010 BMRN Sale $322,047 +18.6%+23.9%+22.6%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Davis George Eric traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.